ESSENCE — citing documents
Every Institute document that draws on this record.
§5Citing documents
This page records every Institute document that draws on ESSENCE. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.
§5.1Monograph evidence extracts
Table 7. Monograph evidence extracts that draw on this trial.
| Compound | Indication | Certainty there |
|---|---|---|
| Semaglutide | Metabolic dysfunction-associated steatohepatitis | Moderate |
§5.2Evidence syntheses
Table 8. Evidence syntheses that include this trial among their contributing studies.
| Synthesis | Review type | Certainty |
|---|---|---|
| Incretin receptor agonists for metabolic dysfunction-associated steatohepatitis | Intervention review | Moderate |
| Completeness of certificates of analysis in the research-supply channel | Analytical evidence review | Moderate |
| Counter-ion content and its effect on delivered peptide mass | Analytical evidence review | High |
| Analytical surveys of unregulated peptide supply | Analytical evidence review | Low |
| The consequences of a wholly sponsor-generated evidence base | Methodological review | Moderate |
| The rodent thyroid C-cell signal and its human relevance | Safety review | Low |
| Reconstitution practice and delivered dose | Analytical evidence review | Moderate |
| Acute pancreatitis with incretin-based therapies | Safety review | Moderate |
| Bacterial endotoxin in research-supply peptide presentations | Analytical evidence review | Low |
| Dependence of reported purity on the analytical method | Analytical evidence review | High |
| In-use stability of reconstituted peptide solutions | Analytical evidence review | Moderate |
§5.3Other records in the same programme
Table 9. Other records in the ESSENCE — semaglutide in steatohepatitis.
| Record | Type | Phase | Status |
|---|---|---|---|
| ESSENCE-PK | Programme record | 1 | Reported |
| ESSENCE-RENAL-IMP | Programme record | 1 | Reported |
| ESSENCE-DDI | Programme record | 1 | Reported |
§5.4Reference
The published report or reports the Institute holds for this trial[1].
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. New England Journal of Medicine 2025;392(21):2089–2099. doi:10.1056/NEJMoa2413258
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.